A groundbreaking cream designed to address the root cause of vitiligo is set to become accessible through the National Health Service in England. Clinical trials have demonstrated the cream’s ability to significantly restore pigmentation in the depigmented skin patches characteristic of vitiligo. This development marks a notable shift, though the treatment has faced previous discussions regarding its use, given that vitiligo itself is not typically associated with physical pain or immediate danger.
David Rosmarin, a researcher at Indiana University who spearheaded two clinical trials for the ruxolitinib cream, highlights the emotional toll of the condition. “Usually, people [with vitiligo] are asymptomatic in terms of physical symptoms, but it can cause a lot of emotional hardship,” he stated. The cream, already available in the United States under the brand name Opzelura, targets non-segmental vitiligo. This form of the condition typically presents as symmetrical white patches appearing on both sides of the body, believed to stem from the immune system erroneously attacking melanocytes – the cells responsible for producing melanin, the pigment that imparts color to the skin.
Emma Rush, representing Vitiligo Support UK, emphasizes the significance of this new treatment. She notes that this topical ruxolitinib is the first drug with robust clinical testing to directly target the specific pathway leading to vitiligo. “That’s why this [recommendation] is such a landmark,” she commented, underscoring its potential impact.
The mechanism of action for ruxolitinib involves inhibiting two key enzymes believed to be involved in the immune cells’ destruction of melanocytes. While established treatments like steroid creams can promote some repigmentation, they tend to suppress the immune system more broadly. In contrast, ruxolitinib offers a more targeted approach.
Findings from two trials, published in 2022, indicated that the ruxolitinib cream improved pigmentation and reduced the visual prominence of vitiligo patches when compared to a placebo cream. These positive outcomes were observed across various skin tones, and importantly, more than a third of participants who discontinued the drug after the trial maintained these repigmentation effects for at least a year.
The National Institute for Health and Care Excellence (NICE) had previously considered these trial results but initially deemed ruxolitinib lacked cost-effectiveness for NHS utilization. The recent decision now supports its availability for individuals aged 12 and older diagnosed with non-segmental vitiligo, particularly when other topical treatments have proven ineffective or are not suitable.
Vitiligo affects approximately one percent of the global population, with varying degrees of severity. Some individuals experience only a few small depigmented areas, while others may have extensive patches that can sometimes present with redness, inflammation, or discoloration.
Viktoria Eleftheriadou from the British Association of Dermatologists acknowledges a common perception that vitiligo, due to its lack of physical pain or life threat, might not warrant treatment. However, she points out that the condition can be linked to significant psychological complications, including an increased risk of depression and anxiety.
Natalie Ambersley, a vitiligo ambassador for the charity Changing Faces, which supports individuals with visible differences, advocates against any stigma associated with seeking treatment for vitiligo. Despite her personal journey with existing treatments over many years, she expresses a personal decision not to pursue ruxolitinib. “I’ve learned to accept my skin,” she shared. “We’re [all] unique and we can embrace what we look like.” Rush acknowledges this sentiment, stating, “It’s great that there are people who love the skin they’re in, but that’s not for everyone.”
Concerns have been raised about an oral formulation of ruxolitinib, which is prescribed for certain cancers and rheumatoid arthritis, due to associated severe side effects such as lymphoma, cardiac issues, and serious infections. Critically, these adverse effects have not been documented with the topical application. During the vitiligo trials, the topical ruxolitinib was associated with only minor side effects, like acne and itchiness. Eleftheriadou assures that “There is super minimal systemic absorption,” indicating a low likelihood of the drug impacting the wider body.
Furthermore, ruxolitinib is considered to possess a safer profile than topical steroid treatments, which can lead to skin thinning with prolonged use. For individuals with severe cases of vitiligo, ultraviolet therapy is an option, though its accessibility remains limited in many areas.